These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Theory and practice for design of transdermal and transmucosal drug delivery systems]. Morimoto K; Morisaka K Nihon Rinsho; 1989 Jun; 47(6):1255-60. PubMed ID: 2769987 [No Abstract] [Full Text] [Related]
23. [Pharmacokinetics of bis-phenyl-(2-chloro-phenyl)-1-imidazolyl-methane-( 14 C) following topical administration]. Duhm B; Maul W; Medenwald H; Patzschke K; Wegner LA; Oberste-Lehn H Arzneimittelforschung; 1972 Aug; 22(8):1276-80. PubMed ID: 4678388 [No Abstract] [Full Text] [Related]
25. Drug formulation and biologic availability. Poole JW Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883 [No Abstract] [Full Text] [Related]
26. Nuclear receptors and unsaturated fatty acids: implications for pharmacologic activity of the galenic forms of topical preparations. Reichrath J Dermatology; 2004; 209(4):348-9. PubMed ID: 15539909 [No Abstract] [Full Text] [Related]
27. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability. Smith EW; Meyer E; Haigh JM Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308 [TBL] [Abstract][Full Text] [Related]
28. Bioavailability: some pharmaceutical factors. Fowle AS Trans Med Soc Lond; 1975; 91():23-32. PubMed ID: 1236035 [No Abstract] [Full Text] [Related]
29. Pickering w/o emulsions: drug release and topical delivery. Frelichowska J; Bolzinger MA; Valour JP; Mouaziz H; Pelletier J; Chevalier Y Int J Pharm; 2009 Feb; 368(1-2):7-15. PubMed ID: 18992799 [TBL] [Abstract][Full Text] [Related]
30. [Clinical study of the biological availability of lanatoside C and digoxin in long-term tests]. Bodem G; Ochs H; Hahn E; Dengler HJ Schweiz Med Wochenschr; 1977 May; 107(19):658-66. PubMed ID: 867012 [TBL] [Abstract][Full Text] [Related]
31. [Effect of liver and testicular functions on the biologic availability of testosterone in various dosage forms]. Cüppers HJ; Wickings EJ; Wiegelmann W; Nieschlag E Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1923-6. PubMed ID: 1030138 [No Abstract] [Full Text] [Related]
32. [Efficient drug forms and the means for using them in the intensive raising of animals]. Drumev D Vet Med Nauki; 1985; 22(10):65-74. PubMed ID: 4090268 [TBL] [Abstract][Full Text] [Related]
33. Enhancement of bioavailability by lowering of fat content in topical formulations. Wirén K; Frithiof H; Sjöqvist C; Lodén M Br J Dermatol; 2009 Mar; 160(3):552-6. PubMed ID: 19120336 [TBL] [Abstract][Full Text] [Related]
34. Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Karim A Angiology; 1983 Jan; 34(1):11-22. PubMed ID: 6401951 [TBL] [Abstract][Full Text] [Related]
35. The general problem of drug bioavailability and its assessment in man. Smith RN Postgrad Med J; 1974 Nov; 50 Suppl 6():7-14. PubMed ID: 4459894 [No Abstract] [Full Text] [Related]
39. [Classical and current principles of external dermatotherapy]. Lüders G Z Hautkr; 1974 Nov; 49(22):945-9. PubMed ID: 4450609 [No Abstract] [Full Text] [Related]
40. [In vitro availability of a topical corticosteroid from various vehicles. Attempt at a correlation with an in vivo study]. Zuber M; Chemtob C; Chaumeil JC J Pharm Belg; 1982; 37(6):393-400. PubMed ID: 7161698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]